Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neuromuscular blockade reversal Clear all
Completed Phase 3 Interventional

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

NCT03513406
View directory record Official record
Conditions
Burns
Interventions
Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

NCT03579589
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex vs Neostigmine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional

Incidence and Severity of Residual Neuromuscular Blockade

NCT02660398
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Standardized NMBD Management
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 30, 2026, 1:17 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuromuscular Blockade in Patients With Severe Renal Impairment

NCT03904550
View directory record Official record
Conditions
Neuromuscular Blockade, Renal Impairment
Interventions
Cisatracurium + Neostigmine, Rocuronium + Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Not applicable Interventional Results available

An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study

NCT04108130
View directory record Official record
Conditions
Postoperative Pulmonary Complications
Interventions
Preoperative Education, Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization, Individualization of Neuromuscular Blockade, Postoperative Incentive Spirometry, Postoperative Ambulation
Other · Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Sep 30, 2026, 1:17 AM EDT
Withdrawn Phase 4 Interventional

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

NCT03226080
View directory record Official record
Conditions
Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions
Rocuronium, Sugammadex, Normal saline
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 30, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Low Pressure Pneumoperitoneum and Postoperative Ileus

NCT05344417
View directory record Official record
Conditions
Postoperative Ileus, Gastrointestinal Dysfunction
Interventions
Pneumoperitoneum Pressure, Neuromuscular blockade, Pneumoperitoneum insufflation device, Neuromuscular blockade reversal
Procedure · Device · Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 30, 2026, 1:17 AM EDT
Completed No phase listed Observational

Suggamadex and Fast-track Cardiac Anesthesia in a Developing Country

NCT02704351
View directory record Official record
Conditions
Suggamadex, Surgery for Congenital Heart Disease
Interventions
Surgery
Procedure
Lead sponsor
Joseph D. Tobias
Other
Eligibility
0 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

NCT03532178
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline, Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

NCT05985343
View directory record Official record
Conditions
Hernia, Ventral, Ileus
Interventions
Neostigmine / Glycopyrrolate, Sugammadex
Drug
Lead sponsor
Clayton Petro
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block

NCT05545280
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neostigmine with glycopyrrolate, Sugammadex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 30, 2026, 1:17 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Residual Neuromuscular Blockade in Cardiac Surgery Patients

NCT03574337
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Sugammadex, neostigmine/glycopyrolate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

NCT04570150
View directory record Official record
Conditions
Anesthesia
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine w/ Glycopyrrolate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

NCT01199237
View directory record Official record
Conditions
Airway Reflexes, Protective, Recovery After Neuromuscular Block, Anesthetic Recovery
Interventions
Sevoflurane, Desflurane, Rocuronium, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Sep 30, 2026, 1:17 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 30, 2026, 1:17 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Comparison of Sugammadex and Neostigmine During PACU Stay

NCT04096144
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neuromuscular Blocking Agents
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 30, 2026, 1:17 AM EDT
Completed No phase listed Observational

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348
View directory record Official record
Conditions
Neuromuscular Blockade, Residual Curarisation, Postoperative, Surgery Under General Anaesthesia
Interventions
Neuromuscular blocking agents
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
265,537 participants
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 30, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Best Management of Muscle Relaxation- Objective Monitoring

NCT03958201
View directory record Official record
Conditions
Residual Paralysis, Post Anesthesia
Interventions
Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 30, 2026, 1:17 AM EDT